PAVmed Inc. Announces Key Results from Special Shareholder Meeting Held March 27, 2026

Key Highlights

• Special Meeting of Shareholders: Held on March 27, 2026, with 54.1% of voting power represented.
• Approval of Significant Corporate Actions: Several proposals were approved that may have material impact on share value and corporate governance.
• Changes to Equity Incentive Plan: Substantial increase in share pool for long-term incentives.
• Amendments to Certificate of Incorporation: Simplifies director removal process, potentially affecting board dynamics.
• Issuance of Common Stock Related to Private Placement & Debt Refinancing: Shareholder approval facilitates conversion of preferred stock and exercise of warrants, which could affect dilution and stock price.

Detailed Analysis of Meeting Outcomes

1. Approval of Stock Issuance Related to Private Placement and Debt Refinancing

Shareholders approved, for Nasdaq Listing Rule 5635 purposes, the issuance of common shares upon conversion of 60,000 shares of Series D Convertible Preferred Stock (par value \$0.001), which were sold in a private placement completed on February 3, 2026, and underlying warrants to purchase Series D Preferred Stock. Also approved was the issuance of shares pursuant to an Amended Restated Senior Secured Convertible Note issued for the redemption of certain preferred stock and refinancing of debt.

Vote Results:

• For: 640,946
• Against: 72,380
• Abstain: 5,055
• Broker Non-Votes: None

Implications: These approvals allow the company to convert preferred stock and warrants into common shares, which could increase the float and potentially dilute existing shareholders. However, it strengthens the balance sheet by refinancing debt and redeeming costly preferred shares. Investors should monitor the effects on share supply and price.

2. Amendment to Certificate of Incorporation—Director Removal

Shareholders approved an amendment to the certificate of incorporation to permit the removal of any director, with or without cause, by a majority vote of outstanding voting power.

Implications: This change gives shareholders more direct influence over board composition and could facilitate governance changes in response to performance or investor sentiment. This is a significant shift in corporate governance and may affect the company’s strategic direction.

3. Expansion of 2014 Long-Term Incentive Equity Plan

The meeting approved an amendment to the company’s 2014 Long-Term Incentive Equity Plan, increasing the number of shares available for issuance from 213,517 to 1,713,517, an increase of 1,500,000 shares.

Vote Results:

• For: 162,305
• Against: 6,530
• Abstain: None
• Broker Non-Votes: None

Implications: This major increase in available shares for incentive awards could enhance the company’s ability to attract and retain talent. However, it also raises dilution concerns and could impact share price if new awards are exercised and additional shares enter the market.

Other Noteworthy Points

• The company’s common stock trades on The Nasdaq Stock Market LLC under symbol PAVM.
• PAVmed Inc. is not classified as an emerging growth company under SEC rules.
• No written communications, soliciting materials, or pre-commencement tender offer communications were filed alongside this report, indicating no additional disclosure obligations triggered by these events.
• Because all proposals were approved, the proposal to adjourn the meeting was not presented.
• Exhibits referenced include the form of the Certificate of Amendment and the Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan, both incorporated by reference to the proxy statement.

Potential Price Sensitivity & Investor Considerations

Shareholder Dilution: Approval of share issuances for conversion and incentive plans could materially increase the number of shares outstanding, potentially impacting share price.

Governance Changes: Easier removal of directors may lead to changes in board composition, which could affect strategic direction and investor confidence.

Balance Sheet Improvements: Debt refinancing and preferred stock redemption may improve financial stability, which could be viewed positively by investors.

Talent Retention: Expanded incentive plan may attract and retain key personnel, supporting future growth, but at the risk of further dilution.

Conclusion

The special meeting’s outcomes are material to both the structure and governance of PAVmed Inc. Investors should closely monitor subsequent SEC filings for the actual issuance of shares, potential board changes, and any impact on the company’s share price and financial performance. These changes could be price sensitive and may affect the valuation and attractiveness of PAVmed Inc. common stock in the short and long term.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisors before making investment decisions. The information provided is based on SEC filings and may be subject to change or interpretation.

View PAVmed Inc. Historical chart here